Literature DB >> 25037140

Combined inhibition of BRAF and MEK in melanoma patients.

Jeffrey R Infante1, Charles Swanton2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25037140     DOI： 10.1016/S1470-2045(14)70331-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.

Authors:  Ruiqin Mai; Songxia Zhou; Weixiang Zhong; Siming Rong; Zhichao Cong; Yunxian Li; Qizhi Xie; Huanming Chen; Xiaoyun Li; Shuhui Liu; Yabin Cheng; Yuanshen Huang; Youwen Zhou; Guohong Zhang
Journal:  Oncotarget       Date:  2015-09-29

2.  Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

Authors:  Luigi Fattore; Debora Malpicci; Emanuele Marra; Francesca Belleudi; Alessia Noto; Claudia De Vitis; Maria Elena Pisanu; Pierpaolo Coluccia; Rosa Camerlingo; Giuseppe Roscilli; Antoni Ribas; Arianna Di Napoli; Maria Rosaria Torrisi; Luigi Aurisicchio; Paolo Antonio Ascierto; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2015-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.